Orthopedic Bone Cement and Casting Material Market to Reach USD 6.7 Bn by 2035

According to analysts at Vantage Market Research, the Global orthopedic bone cement and casting material Market size is worth USD 3.4 Billion in 2024 and is projected to reach USD 6.7 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 8.8% from 2025 to 2035. Key trends of market include increasing Popularity of Lightweight and Water-Resistant Casting Materials, technological Integration for Precision and Customization, and Rising Sports Injuries and Trauma Cases. 

Market Overview

The orthopedic bone cement and casting material market focuses on products used in the stabilization and repair of bone fractures and joint replacements. Orthopedic bone cement is primarily used to anchor implants and fill gaps between bones and prostheses in joint replacement surgeries, helping to ensure stability and promote healing. Casting materials, on the other hand, are used to immobilize and protect fractured bones, facilitating proper alignment and healing. With the growing popularity of sports activities and the rise in road traffic, the incidence of fractures and musculoskeletal injuries has surged. Orthopedic bone cement and casting materials play a vital role in the management of these injuries by providing immobilization, stability, and support to the affected bones and joints.

The modern casting materials offer several benefits, including being lighter, more durable, and resistant to water, which improves patient comfort and mobility during the healing process. Additionally, these materials are often more breathable, reducing the risk of skin irritation and enhancing overall hygiene. Advances in the formulation of these casting materials also include the development of casts that provide better fit and support, with some even allowing for digital customization through 3D scanning.

DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures

• In June 2024, Johnson & Johnson MedTech announced that DePuy Synthes, the orthopedic division of Johnson & Johnson, has received 510(k) FDA clearance for the clinical use of the VELYS™ Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty (UKA). This expanded indication builds on the VELYS platform, which is already approved for Total Knee Arthroplasty (TKA) and has been cleared for use in 20 markets, with over 55,000 procedures performed. The VELYS system provides surgeons with critical information to help preserve the soft tissue envelope, predict joint stability, and facilitate the restoration of knee function

Key Takeaways from the Report

• In 2024, North America dominated the market with 46.20% market share. The market is driven by aging population, sedentary lifestyles, and sports-related injuries
• Based on the Product, the Bone Cement category accounted for significant market share of 54.10%. The segment is driven by increased demand for joint trauma surgeries, and replacement procedures
• Based on the Application, the Joint Arthroplasty category accounted for significant market share of 38.40%. The segment is driven by the rising demand for joint replacement surgeries, encourage by an aging population and advancements in arthroplasty techniques
• By End User, Hospitals dominated the market with significant market share of 56.20%. Hospitals are equipped with well-established orthopedic departments that feature specialized infrastructure and resources

Top Companies

• DePuy Chemicals
• 3M Healthcare Ltd.
• Stryker Corporation
• Biomet Inc
• Smith & Nephew Plc
• Exactech Inc
• Zimmer Holdings Inc.
• Orthofix International S.V.
• BSN Medical GmbH

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Zimmer Biomet Signs Definitive Agreement to Acquire OrthoGrid Systems Inc.

• In August 2024, Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced today that it has signed a definitive agreement to acquire OrthoGrid Systems, Inc. (OrthoGrid), a privately-held company specializing in AI-driven surgical guidance systems for total hip replacement. This acquisition includes OrthoGrid's AI-powered, fluoroscopy-based surgical assistance platform, HIP AI, along with two additional FDA-cleared orthopedic applications and a portfolio of over 40 patents